Pricing Log in Create free account

Gilead Sciences, Inc. (GILD) vs Sanofi (SNY)

Gilead Sciences, Inc. and Sanofi are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $205.4B against $102.8B — 2.0× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Sanofi trades at 23.3×. Sanofi grew revenue faster over the last twelve months: 21.3% against 5.52%. Sanofi has the higher net margin (8.22% vs −10.6%) and the higher return on invested capital (6.58% vs −4.48%). Both pay a dividend; Sanofi yields more (5.45% vs 1.90%). Across the 22 metrics below, Sanofi leads on 17 and Gilead Sciences, Inc. on 5.

Valuation

Metric GILD SNY Drug Manufacturers General median
P/E n/m 23.26 27.65
P/S 6.97 1.87 3.59
P/B 18.08 1.31 5.14
Price to free cash flow 16.41 7.31 17.06
EV/EBITDA 898.55 11.95 15.32
EV/Sales 7.73 2.18 4.34
Earnings yield (1.52%) 4.30% 2.82%
Free cash flow yield 6.10% 13.68% 4.34%

Profitability

Metric GILD SNY Drug Manufacturers General median
Gross margin 79.59% 72.78% 72.77%
Operating margin (8.20%) 18.24% 18.77%
Net margin (10.64%) 8.22% 8.27%
Free cash flow margin 42.50% 25.53% 17.18%
Return on equity (20.68%) 5.87% 5.87%
Return on assets (6.17%) 3.21% 2.57%
Return on invested capital (4.48%) 6.58% 6.11%

Growth

Metric GILD SNY Drug Manufacturers General median
Revenue growth (TTM) 5.52% 21.30% 6.66%
EPS growth (last fiscal year) 1,684.21% 45.97% 21.81%
Revenue growth, 5-year CAGR 3.58% 4.37% 4.75%
Net income growth, 5-year CAGR 133.35% (8.87%) 0.00%

Health

Metric GILD SNY Drug Manufacturers General median
Debt to equity 2.23 0.31 0.63
Current ratio 1.27 0.99 1.32
Net debt to EBITDA 1.35 0.76 1.15

Dividend

Metric GILD SNY Drug Manufacturers General median
Dividend yield 1.90% 5.45% 2.27%
Payout ratio — 1.27 0.59

Size

Metric GILD SNY Drug Manufacturers General median
Market cap 205.35b 102.80b 125.40b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack